A randomized, double-blind, crossover comparison of MK-0929 and placebo in the treatment of adults with ADHD.
Preclinical models, receptor localization, and genetic linkage data support the role of D4 receptors in the etiology of ADHD. This proof-of-concept study was designed to evaluate MK-0929, a selective D4 receptor antagonist as treatment for adult ADHD. A randomized, double-blind, placebo-controlled, crossover study was conducted in adults with primary ADHD. The primary end point was changed from baseline in total score on the Adult ADHD Investigator Symptom Rating Scale following a 4-week treatment regimen. Additional measures included Clinical Global Impression-Severity Scale, Hospital Anxiety and Depression Scale, and Brown Attention Deficit Disorder Scale and D4 genotype analysis. No statistically significant treatment differences were found between MK-0929 and placebo in any of the primary or secondary assessments. Results from this study suggest that blockade of the D4 receptor alone is not efficacious in the treatment of adult ADHD.